Published in Nature on December 04, 1997
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol (2007) 3.16
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A (1999) 2.32
Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci U S A (2004) 2.23
Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am J Physiol Heart Circ Physiol (2004) 1.88
Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol (2005) 1.76
Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J (2000) 1.75
Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol (2007) 1.65
Cannabinoids and neuroinflammation. Br J Pharmacol (2004) 1.62
The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol (2004) 1.56
Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci U S A (1999) 1.51
Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J Physiol (2004) 1.51
The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J (2005) 1.50
Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells. Br J Pharmacol (2003) 1.31
Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis (2003) 1.29
Endocannabinoids in liver disease. Hepatology (2011) 1.27
The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol (2007) 1.25
Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology (2005) 1.23
Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol (2007) 1.22
Anandamide-induced mobilization of cytosolic Ca2+ in endothelial cells. Br J Pharmacol (1999) 1.14
Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol (2005) 1.14
The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol (2010) 1.11
Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). Br J Pharmacol (2004) 1.06
CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. Br J Pharmacol (2003) 1.02
Anandamide induces cardiovascular and respiratory reflexes via vasosensory nerves in the anaesthetized rat. Br J Pharmacol (2001) 1.02
Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol (2007) 1.01
Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans. Neuropsychopharmacology (2012) 1.00
Vascular effects of anandamide and N-acylvanillylamines in the human forearm and skin microcirculation. Br J Pharmacol (2005) 1.00
Cannabinoid receptors in acute and chronic complications of atherosclerosis. Br J Pharmacol (2007) 1.00
Endocannabinoids and the haematological system. Br J Pharmacol (2007) 0.94
CB2 cannabinoid receptors contribute to bacterial invasion and mortality in polymicrobial sepsis. PLoS One (2009) 0.94
Cannabinoid CB1 receptors fail to cause relaxation, but couple via Gi/Go to the inhibition of adenylyl cyclase in carotid artery smooth muscle. Br J Pharmacol (1999) 0.94
Endocannabinoids and the heart. J Cardiovasc Pharmacol (2009) 0.94
Cannabidiol inhibits angiogenesis by multiple mechanisms. Br J Pharmacol (2012) 0.89
Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats. Br J Pharmacol (2009) 0.88
Production of the endocannabinoids anandamide and 2-arachidonoylglycerol by endothelial progenitor cells. FEBS Lett (2007) 0.88
Effects of AM281, a cannabinoid antagonist, on circulatory deterioration and cytokine production in an endotoxin shock model: comparison with norepinephrine. J Anesth (2006) 0.85
Reduced endothelium-dependent relaxation to anandamide in mesenteric arteries from young obese Zucker rats. PLoS One (2013) 0.84
Endocannabinoids and cardiac contractile function: pathophysiological implications. Pharmacol Res (2009) 0.84
Transient receptor potential vanilloid 1 antagonist, capsazepine, improves survival in a rat hemorrhagic shock model. Ann Surg (2007) 0.84
Search for an endogenous cannabinoid-mediated effect in the sympathetic nervous system. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.83
Endocannabinoid signaling in midbrain dopamine neurons: more than physiology? Curr Neuropharmacol (2007) 0.82
Cardiorespiratory anomalies in mice lacking CB1 cannabinoid receptors. PLoS One (2014) 0.81
Circulating endocannabinoid concentrations during orthostatic stress. Clin Auton Res (2009) 0.80
Cannabis and endocannabinoid modulators: Therapeutic promises and challenges. Clin Neurosci Res (2005) 0.80
TRPV1 mediates cellular uptake of anandamide and thus promotes endothelial cell proliferation and network-formation. Biol Open (2014) 0.79
Endocannabinoids in cerebrovascular regulation. Am J Physiol Heart Circ Physiol (2016) 0.79
Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities. J Pharm Bioallied Sci (2011) 0.77
Presynaptic cannabinoid CB(1) receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats. Br J Pharmacol (2004) 0.77
Migraine: an overview. Open Neurol J (2009) 0.77
Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716). Naunyn Schmiedebergs Arch Pharmacol (2008) 0.76
Differential Regulation of Eicosanoid and Endocannabinoid Production by Inflammatory Mediators in Human Choriodecidua. PLoS One (2016) 0.75
Blunted cardiac response to hemorrhage in cirrhotic rats is mediated by local macrophage-released endocannabinoids. J Hepatol (2015) 0.75
Sensitization of C-fiber nociceptors in mice with sickle cell disease is decreased by local inhibition of anandamide hydrolysis. Pain (2017) 0.75
Phospholipids in mitochondrial dysfunction during hemorrhagic shock. J Bioenerg Biomembr (2016) 0.75
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A (2001) 7.15
Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (2001) 6.36
Regulation of adipose tissue pyruvate dehydrogenase by insulin and other hormones. Biochem J (1971) 4.50
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
The association of viral and bacterial respiratory infections with exacerbations of wheezing in young asthmatic children. J Pediatr (1973) 4.22
Stimulation by calcium ions of pyruvate dehydrogenase phosphate phosphatase. Biochem J (1972) 4.05
Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A (1999) 3.54
Improved lactose digestion and intolerance among African-American adolescent girls fed a dairy-rich diet. J Am Diet Assoc (2000) 2.94
Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther (1996) 2.90
Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron (2001) 2.81
The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther (1994) 2.55
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther (1993) 2.40
Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A2. Science (1976) 2.39
Pharmacokinetics of theophylline in children with asthma. Pediatrics (1976) 2.31
Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther (2000) 2.26
Relationship between theophylline concentration in plasma and saliva of man. Clin Pharmacol Ther (1974) 2.26
Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol (2001) 2.22
Role of adenine and guanine nucleotides in the activity and response of adenylate cyclase systems to hormones: evidence for multisite transition states. Adv Cyclic Nucleotide Res (1975) 2.06
Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs. J Pharmacol Exp Ther (2008) 2.04
Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem (2000) 2.04
Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension (1999) 2.03
The role of the spleen in immunity. With special reference to the post-splenectomy problem in infants. Pediatrics (1966) 2.01
Mechanisms regulating adipose-tissue pyruvate dehydrogenase. Biochem J (1972) 2.01
Continuous infusion of pyridostigmine in the management of myasthenic crisis. Crit Care Med (1993) 1.99
Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther (1998) 1.97
Evidence favouring the existence of a single adrenergic receptor. Nature (1968) 1.96
Cannabis: pharmacology and toxicology in animals and humans. Addiction (1996) 1.89
Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J (1998) 1.89
Distinct patterns of DeltaFosB induction in brain by drugs of abuse. Synapse (2008) 1.87
Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther (1997) 1.87
In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther (1996) 1.85
Nicotine dependence and reward differ between adolescent and adult male mice. J Pharmacol Exp Ther (2007) 1.81
Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med (2001) 1.80
Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther (1992) 1.76
Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J (2000) 1.75
Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension (1997) 1.75
Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol (1996) 1.75
3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem (1999) 1.73
Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol (1995) 1.72
Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J Pharmacol Exp Ther (2003) 1.64
Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry (2012) 1.63
Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther (1988) 1.58
Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther (1996) 1.55
Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend (2000) 1.55
Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. J Pharmacol Exp Ther (1994) 1.52
Effect of antibody upon clearance of I-125-labelled pneumococci by the spleen and liver. Pediatr Res (1967) 1.48
A simple enzymic method for the synthesis of adenosine 5'-[alpha-32P]triphosphate on a preparative scale. Biochem J (1977) 1.47
Evidence that the antinociceptive tail-flick response is produced independently from changes in either tail-skin temperature or core temperature. Pain (1993) 1.46
Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension (1996) 1.46
PGH synthase and lipoxygenase generate superoxide in the presence of NADH or NADPH. Circ Res (1986) 1.44
Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol (2001) 1.42
Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem (1999) 1.42
Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther (1992) 1.41
Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther (2005) 1.39
Controlled study of iodotherapy for childhood asthma. J Allergy (1966) 1.39
Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl) (1995) 1.38
Evidence against leukotrienes as mediators of brain edema. J Neurosurg (1991) 1.38
Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther (1998) 1.37
Cost and survival results of critical care regionalization for Medicare patients. Crit Care Med (1989) 1.37
Cannabinoid tolerance and dependence. Handb Exp Pharmacol (2005) 1.35
Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol (2001) 1.35
Insulin inhibits the cholera-toxin-catalysed ribosylation of a Mr-25000 protein in rat liver plasma membranes. Biochem J (1985) 1.35
Racial differences in bone turnover and calcium metabolism in adolescent females. J Clin Endocrinol Metab (2003) 1.31
Insulin activates pyruvate dehydrogenase in rat epididymal adipose tissue. Nat New Biol (1971) 1.31
Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J Pharmacol Exp Ther (1998) 1.31
Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol (1992) 1.30
Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol (1999) 1.30
Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol (2001) 1.29
The antinociceptive effects of alpha7 nicotinic agonists in an acute pain model. Neuropharmacology (2000) 1.28
Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther (1995) 1.28
Asthma in childhood. J Allergy Clin Immunol (1983) 1.27
Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther (2001) 1.27
Metabolism of pyruvate and malate by isolated fat-cell mitochondria. Biochem J (1971) 1.26
Effects of insulin and adrenaline on rat epididymal-fat-pad pyruvate dehydrogenase. Biochem J (1971) 1.26
Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology (Berl) (1996) 1.25
Cerebral arteriolar damage by arachidonic acid and prostaglandin G2. Science (1980) 1.25
Soy isoflavones do not affect bone resorption in postmenopausal women: a dose-response study using a novel approach with 41Ca. J Clin Endocrinol Metab (2006) 1.24
The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther (1997) 1.24
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. J Clin Endocrinol Metab (2009) 1.22
Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice. J Pharmacol Exp Ther (1998) 1.22
Melanocortin antagonists define two distinct pathways of cardiovascular control by alpha- and gamma-melanocyte-stimulating hormones. J Neurosci (1996) 1.22
Appearance of superoxide anion radical in cerebral extracellular space during increased prostaglandin synthesis in cats. Circ Res (1985) 1.19
Calcium influx factor, further evidence it is 5, 6-epoxyeicosatrienoic acid. J Biol Chem (1999) 1.19
Metabolism of arachidonic acid to epoxyeicosatrienoic acids, hydroxyeicosatetraenoic acids, and prostaglandins in cultured rat hippocampal astrocytes. J Neurochem (1993) 1.19
Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem (1996) 1.19